Y. Kumagae

发表

In vivo conversion of racemized β‐amyloid ([D‐Ser26]Aβ1–40) to truncated and toxic fragments ([D‐Ser26]Aβ25–35/40) and fragment presence in the brains of Alzheimer's patients

T. Kubo, Satoko Nishimura, I. Kaneko, 2002 .

A novel model of type 2 diabetes mellitus based on obesity induced by high-fat diet in BDF1 mice.

H. Karasawa, Y. Kumagae, Seiko Nagata-Goto, 2009, Metabolism: clinical and experimental.

Human c-Jun N-terminal kinase expression and activation in the nervous system.

C. Miller, Y. Zhang, Y. Kumagae, 1999, Brain research. Molecular brain research.

Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia

Y. Kumagae, Y. Matsui, 1991, Neuroscience Letters.

Participation of type A monoamine oxidase in the activated deamination of brain monoamines shortly after reperfusion in rats.

Y. Kumagae, N. Iwata, Y. Matsui, 1990, Japanese journal of pharmacology.

Output, Tissue Levels, and Synthesis of Acetylcholine During and After Transient Forebrain Ischemia in the Rat

Y. Kumagae, Y. Matsui, Yoshihiro Kumagae, 1991, Journal of neurochemistry.

Obesity‐Induced Diabetes in Mouse Strains Treated With Gold Thioglucose: A Novel Animal Model for Studying β‐Cell Dysfunction

H. Karasawa, Y. Kumagae, K. Takaishi, 2011, Obesity.

β‐Amyloid Racemized at the Ser26 Residue in the Brains of Patients with Alzheimer Disease: Implications in the Pathogenesis of Alzheimer Disease

Isao Kaneko, T. Kubo, I. Kaneko, 2003, Journal of neuropathology and experimental neurology.

In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients.

T. Kubo, Satoko Nishimura, I. Kaneko, 2002, Journal of neuroscience research.

Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.

Y. Kumagae, N. Iwata, Y. Matsui, 1991, Japanese journal of pharmacology.

Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease.

S. Marumoto, H. Kogen, K. Koyama, 2003, Journal of pharmacological sciences.